BriaCell (BCTX) Phase 3 Trial Safety Endorsement Highlights Market's Cautious Outlook
On September 14, 2026, BriaCell Therapeutics Corp (BCTX) announced that the independent Data Safety Monitoring Board (DSMB) has issued its seventh consecutive r
NASDAQ
BCTX Research Hub
BriaCell Therapeutics Corp.
Latest signal
8-K filed 2026-06-26
8-K
PennyIntel health score
6.8/10
Higher is healthier / lower risk. Watch closely
What to watch next
Current focus: FDA study clearance. Verify the latest SEC source, financing language, compliance status, ownership changes, and any follow-up news before making a move.
PennyIntel post
BCTX setup note
August 5 release says FDA issued Study May Proceed clearance for Bria-PROS+ in prostate cancer.
What to watch: Current focus: FDA study clearance. Verify the latest SEC source, financing language, compliance status, ownership changes, and any follow-up news before making a move.
Notification preview
Signals worth watching
Subscriber-worthy news change
7 caution-tone articles detected. Main tag: FDA/clinical.
8-K filed 2026-06-26
8-K
Dilution safety at 4/10
This is the weakest current PennyIntel check. Put alerts on financing, proxy, compliance, and ownership changes before treating the setup as clean.
What should trigger a follow-up
Current focus: FDA study clearance. Verify the latest SEC source, financing language, compliance status, ownership changes, and any follow-up news before making a move.
Follow this ticker to track news, SEC changes, ownership activity, catalysts, risk moves, and active discussion in one place.
Community pulse
BCTX trader notes
No trader notes yet for BCTX. Be first to add a filing note, catalyst watch, or risk warning.
Checking account...
Marketaux news pulse
Latest related coverage
FDA/clinical
Compliance
Offering/dilution
Contract/order
Earnings/results
BriaCell (BCTX) Phase 3 Trial Safety Endorsement Highlights Market's Cautious Outlook
On September 14, 2026, BriaCell Therapeutics Corp (BCTX) announced that the independent Data Safety Monitoring Board (DSMB) has issued its seventh consecutive r
On September 14, 2026, BriaCell[+265 characters]
FDA/clinical
Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study
Independent DSMB reports no safety concerns to date and recommends continuing BriaCell's pivotal Phase 3 study of Bria-IMT™ plus an immune checkpoint inhibitorSeventh consecutive positive DSMB recommendation reinforces the favorable safety and tolerability of BriaCell's novel immunotherapy approachPhase 3 study is being conducted under FDA Fast Track de...
consecutive positive DSMB recommendation[+328 characters]
Compliance
FDA/clinical
BriaCell Therapeutics Announces Closing of Offering
PHILADELPHIA & VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) ('BriaCell” or the 'Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the closing of its best-efforts offering of 1,449,300 common s...
PHILADELPHIA & VANCOUVER, British Columb[+92 characters]
Offering/dilution
Compliance
FDA/clinical
BriaCell Therapeutics Announces Pricing of Offering
PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) ('BriaCell” or the 'Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common sh...
PHILADELPHIA and VANCOUVER, British Colu[+93 characters]
Offering/dilution
Compliance
FDA/clinical
BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer
FDA clearance of Investigational New Drug (IND) application opens path to commence Phase 1/2a clinical study for Bria-BRES+ in metastatic breast cancerBria-BRES+ is BriaCell’s next generation personalized immunotherapy for breast cancer, and features additional immune activating components designed to enhance clinical efficacy BriaCell has prepared clin...
immunotherapy for breast cancer, and fea[+335 characters]
Offering/dilution
Compliance
FDA/clinical
BriaCell Announces Six Clinical Data Presentations at ASCO 2026
Final randomized Phase 2 Bria-IMT™ survival and quality of life data to be presentedBiomarker analyses from the ongoing Phase 3 study evaluating predictors of response PHILADELPHIA and VANCOUVER, British Columbia, April 27, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ('BriaCell” or the 'Company”), a clinical...
Final randomized Phase 2 Bria-IMT™ sur[+268 characters]
Compliance
FDA/clinical
Key risk and catalyst checks
New 8-K detected: review for material event, financing, merger, or compliance language
10-Q detected: check cash runway, going-concern language, and share count changes
New 8-K detected: review for material event, financing, merger, or compliance language
424B5 detected: possible financing or resale-share filing
New 8-K detected: review for material event, financing, merger, or compliance language
Reverse split watch
DEF 14A